Although, in southern Europe, there has been considerable experience in the treatment of
visceral leishmaniasis (VL) in HIV-positive patients, the optimal therapy has yet to be …

Treatment of visceral leishmaniasis in HIV patients encounters inefficacy and relapse due to
drug resistance, toxicity and immunodepression. Our goal was to evaluate treatment of these …

This article summarises the clinical features of visceral, cutaneous and mucocutaneous
leishmaniasis, and leishmaniasis in HIV-coinfected patients. The characteristics and clinical …

Objective We conducted a systematic literature review with indirect comparison of studies
evaluating therapeutic efficacy and toxicity associated to visceral leishmaniasis (VL) therapy …

Liposomal amphotericin B has been used with increasing frequency to treat visceral
leishmaniasis (VL). It is the treatment of choice for immunocompetent patients in the …

Optimal treatment for HIV-related visceral leishmaniasis (VL) has still to be established. A
pilot clinical trial was carried out in 57 HIV–VL coinfected patients to compare the efficacy …

Background: Visceral leishmaniasis is common in patients with HIV infection living in
endemic areas, but the most effective and safe treatment remains unknown. Objective: To …

Pentavalent antimonial drugs are habitually the first choice for treating leishmaniasis,
although they possess well-known toxicity and may present some therapeutic failure. Lipid …

Objectives: Visceral leishmaniasis (VL) in HIV-positive patients is characterized by a chronic
course with frequent relapse. The aim of this study was to evaluate the efficacy and safety of …

Visceral leishmaniasis (VL) in patients coinfected with human immunodeficiency virus (HIV)
is often atypical, and characteristically relapses after treatment. We treated 10 HIV infected …